Nightingale: Risk investors must play the waiting game
Commercialization of Nightingale’s technology is still progressing on a broad front. The story combining the company’s high risks and potential has, in our opinion, only strengthened after the IPO. Pricing of future promises has fallen dramatically as the time horizon has shortened on the market, which is also reflected in Nightingale. Concrete supporting points for the company's valuation can in the short term already be found in the balance sheet focusing on cash (2022e P/B 1.2x).
Nightingale Health
Nightingale Health operates in medical technology. The company specializes in the development of medical devices. The product portfolio is broad and includes platforms and services in blood tests that are used for disease prevention purposes. In addition to the main business, service and associated ancillary services are also offered. The business is run globally with the largest presence in Europe.
Read more on company pageKey Estimate Figures2022-02-25
2021 | 22e | 23e | |
---|---|---|---|
Revenue | 2.1 | 3.0 | 8.9 |
growth-% | 31.88 % | 43.68 % | 197.16 % |
EBIT (adj.) | -5.3 | -10.2 | -13.7 |
EBIT-% (adj.) | -253.63 % | -339.82 % | -154.69 % |
EPS (adj.) | -0.13 | -0.18 | -0.23 |
Dividend | 0.00 | 0.00 | 0.00 |
Dividend % | |||
P/E (adj.) | - | - | - |
EV/EBITDA | - | - | - |